194 related articles for article (PubMed ID: 29440231)
1.
Daskalakis K; Norlén O; Karakatsanis A; Hellman P; Larsson R; Nygren P; Stålberg P
Endocr Relat Cancer; 2018 Apr; 25(4):471-480. PubMed ID: 29440231
[TBL] [Abstract][Full Text] [Related]
2. EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Barazeghi E; Hellman P; Norlén O; Westin G; Stålberg P
Sci Rep; 2021 Nov; 11(1):22733. PubMed ID: 34815475
[TBL] [Abstract][Full Text] [Related]
3. Neuropilin-2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors.
Bollard J; Patte C; Radkova K; Massoma P; Chardon L; Valantin J; Gadot N; Goddard I; Vercherat C; Hervieu V; Gouysse G; Poncet G; Scoazec JY; Walter T; Roche C
J Pathol; 2019 Nov; 249(3):343-355. PubMed ID: 31257576
[TBL] [Abstract][Full Text] [Related]
4. Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy.
Hultman B; Mahteme H; Sundbom M; Ljungman M; Larsson R; Nygren P
J Exp Clin Cancer Res; 2014 Dec; 33(1):110. PubMed ID: 25528067
[TBL] [Abstract][Full Text] [Related]
5. Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer.
Cashin PH; Mahteme H; Graf W; Karlsson H; Larsson R; Nygren P
BMC Cancer; 2013 Sep; 13():435. PubMed ID: 24063788
[TBL] [Abstract][Full Text] [Related]
6. Update on medical treatment of small intestinal neuroendocrine tumors.
Pusceddu S; Femia D; Lo Russo G; Ortolani S; Milione M; Maccauro M; Vernieri C; Prinzi N; Concas L; Leuzzi L; De Braud F; Buzzoni R
Expert Rev Anticancer Ther; 2016 Sep; 16(9):969-76. PubMed ID: 27353232
[TBL] [Abstract][Full Text] [Related]
7. DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors.
Edfeldt K; Daskalakis K; Bäcklin C; Norlén O; Tiensuu Janson E; Westin G; Hellman P; Stålberg P
Neuroendocrinology; 2017; 105(2):170-181. PubMed ID: 27829249
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
[TBL] [Abstract][Full Text] [Related]
9. [Mid gut neuroendocrine tumors: News on medical treatment].
Dior M; Dreanic J; Prieux-Klotz C; Brieau B; Brezault C; Coriat R
Presse Med; 2017 Jan; 46(1):4-10. PubMed ID: 28089247
[TBL] [Abstract][Full Text] [Related]
10. Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours.
Söderquist F; Janson ET; Rasmusson AJ; Ali A; Stridsberg M; Cunningham JL
PLoS One; 2016; 11(10):e0164354. PubMed ID: 27736994
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
[TBL] [Abstract][Full Text] [Related]
12. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Fotouhi O; Kjellin H; Juhlin CC; Pan Y; Vesterlund M; Ghaderi M; Yousef A; Andersson-Sand H; Kharaziha P; Caramuta S; Kjellman M; Zedenius J; Larsson C; Orre LM
Oncogene; 2019 Oct; 38(43):6881-6897. PubMed ID: 31406256
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
[TBL] [Abstract][Full Text] [Related]
14. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Flaum N; Valle JW; Mansoor W; McNamara MG
Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
[TBL] [Abstract][Full Text] [Related]
15. Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum.
Blažević A; Hofland J; Hofland LJ; Feelders RA; de Herder WW
Endocr Relat Cancer; 2018 Mar; 25(3):R115-R130. PubMed ID: 29233841
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a heritable contribution to neuroendocrine tumors of the small intestine.
Neklason DW; VanDerslice J; Curtin K; Cannon-Albright LA
Endocr Relat Cancer; 2016 Feb; 23(2):93-100. PubMed ID: 26604321
[TBL] [Abstract][Full Text] [Related]
17. Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.
Kim MK; Ye F; Wang D; Cui M; Ward SC; Warner RR; Roayaie S; Shafir M; Schwartz M; Zhang D; Itzkowitz S
Pancreas; 2016 Apr; 45(4):528-32. PubMed ID: 26474427
[TBL] [Abstract][Full Text] [Related]
18. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
19. A plausible role for actin gamma smooth muscle 2 (ACTG2) in small intestinal neuroendocrine tumorigenesis.
Edfeldt K; Hellman P; Westin G; Stalberg P
BMC Endocr Disord; 2016 Apr; 16():19. PubMed ID: 27107594
[TBL] [Abstract][Full Text] [Related]
20. Advances in small bowel neuroendocrine neoplasia.
Banck MS; Beutler AS
Curr Opin Gastroenterol; 2014 Mar; 30(2):163-7. PubMed ID: 24441281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
